Impact of extramedullary multiple myeloma [EMD] on outcomes with idecabtagene vicleucel - Saurabh Zanwar et al. #ASCO24 Abstract 7508 meetings.asco.org/abstracts-pres… #mmsm #CARTcell HT Dr. Jeffrey Zonder

Cannot over-emphasize the importance of this. In the USA to optimize outcomes in #ATTR #amyloidosis therapy, this has to kept in mind at all times. Equal access to diagnostic testing, to SOC therapy, and to trials #ISA2024 The International Society Of Amyloidosis

M. Bolton LARVOL ASCO Sharlene Gill, MD, MPH, MBA, FASCO Dr Amol Akhade Dr. Estela Rodriguez Enrique Grande Mike Thompson, MD, PhD, FASCO Patrick Forde Corinne Faivre-Finn 💙 Jarushka Naidoo Dr. Nina Niu Sanford Updated

Myeloma / Plasma Cell Dyscrasia ~ #ASCO24 Top10 (or so) #mmsm #mmMRD #ASCO24 - Mike Thompson, MD, PhD, FASCO *DRAFT* Table Update: May 29, 2024 v2 - cc Surviving Myeloma Joseph Mikhael Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Rahul Banerjee, MD, FACP C. Ola Landgren, M.D. Meera Mohan Luciano J Costa @MyelomaTeacher - Cindy Chmielewski Keith Stockerl-Goldstein, MD 😷 Vincent Rajkumar Binod Dhakal

T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) & bispecific T-cell engager (BiTE) therapies & efficacy/toxicity in RRMM - Theprungsirikul et al. #ASCO24 Abstract 7549
meetings.asco.org/abstracts-pres… #mmsm #CARTcell #ImmunoOnc

Top Influencers of #mmMRD [5/29/24; last 7d by SymplurRank]👉 Mike Thompson, MD, PhD, FASCO Joseph Mikhael Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Surviving Myeloma Rahul Banerjee, MD, FACP @MyelomaTeacher - Cindy Chmielewski Meera Mohan C. Ola Landgren, M.D. Keith Stockerl-Goldstein, MD 😷
Luciano J Costa hcsm.io/2SeYcGh via Symplur #mmsm

As you prepare to come to Chicago for #ASCO24 , consider taking the “L” from OHare to Downtown and avoiding taxi lines and rush hour traffic. Everything you need to know: transitchicago.com/airports/ OHare has great signage and helpful staff in the airport if you have questions

Congrats to our Myeloma Fellows Drs. Ross Firestone and Eric Jurgens for receiving the Conquer Cancer, the ASCO Foundation Young investigator Awards this year #ASCO24 #mmsm Memorial Sloan Kettering Cancer Center MSK Department of Medicine Neha Korde Urvi Shah Carlyn Tan Malin Hultcrantz MD PhD Sridevi Rajeeve, MD AlexanderLesokhin MD Hamza Hashmi

Consensus guidelines and recommendations for the management and response assessment of CAR T-cell therapy in RRMM: a report from the International Myeloma Working Group Immunotherapy Committee - ScienceDirect sciencedirect.com/science/articl…

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - Ben Derman et al. Andrzej Jakubowiak #ASCO24 Abstract 106 meetings.asco.org/abstracts-pres… #NCT04108624 #mmsm #mmMRD

A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] International Myeloma Foundation
myeloma.org/blog/dr-duries… #mmMRD #mmsm #ctsm FDA Oncology

Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma [Jul 11, 2022] Ben Derman Andrzej Jakubowiak Mike Thompson, MD, PhD, FASCO Blood Cancer Journal nature.com/articles/s4140… #mmMRD #mmsm #openaccess

Clinician attitudes and practices toward measurable residual disease in multiple myeloma [Jun 7, 2020] Ben Derman Jagoda Andrzej Jakubowiak Brit J Haematol ow.ly/3GSO50Cr8Mc #mmsm #mmMRD

#mmMRD healthcare social media hashtag [Nov 21, 2020] Minimal/measurable residual disease (MRD) in multiple myeloma. Submitted by Ben Derman to Symplur Healthcare Hashtag Project symplur.com/healthcare-has… #mmsm

Association between social determinants of health and time to treatment for newly diagnosed multiple myeloma -Hamlet Gasoyan et al. #ASCO24 Abstract 1583 meetings.asco.org/abstracts-pres… #mmsm #hpeonc

Heartfelt congratulations to this bright, talented class of Conquer Cancer, the ASCO Foundation Grant & Award recipients #ASCO24

The rest of my top 10 #mmsm #ASCO24 abstracts Mike Thompson, MD, PhD, FASCO
In addition to #7572 Lessans-Cardiac transplant outcomes in AL and #7571 Liu-DM and MGUS progression
(in no particular order)
#bmtsm #celltherapy #cartcells #cellulartherapy

Myeloma / Plasma Cell Dyscrasia ~ #ASCO24 Top10 (or so) #mmsm #mmMRD #ASCO24 - Mike Thompson, MD, PhD, FASCO *DRAFT* Table Update: May 28, 2024 - cc Surviving Myeloma Joseph Mikhael Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Rahul Banerjee, MD, FACP C. Ola Landgren, M.D. Meera Mohan Luciano J Costa @MyelomaTeacher - Cindy Chmielewski Keith Stockerl-Goldstein, MD 😷

#IDonc